IPHA logo

IPHA
Innate Pharma

1,491
Mkt Cap
$128.44M
Volume
17,252.00
52W High
$2.63
52W Low
$1.17
PE Ratio
-2.23
IPHA Fundamentals
Price
$1.37
Prev Close
$1.35
Open
$1.33
50D MA
$1.58
Beta
0.48
Avg. Volume
21,694.41
EPS (Annual)
-$0.6195
P/B
-5.04
Rev/Employee
$19,296.61
$143.00
Loading...
Loading...
News
all
press releases
Innate Pharma to Participate in the Kempen Life Sciences Conference
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced...
Business Wire·15h ago
News Placeholder
More News
News Placeholder
Innate Pharma Files Its 2025 Universal Registration Document (Document Denregistrement Universel) and 2025 Form 20-f Annual Report
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced the filing of its 2025 Universal Registration Document (Document denregistrement...
Business Wire·1d ago
News Placeholder
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Sees Large Decline in Short Interest
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Get Free Report) saw a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 76,183 shares, a...
MarketBeat·5d ago
News Placeholder
Innate Pharma Q4 Earnings Call Highlights
Innate Pharma (NASDAQ:IPHA) outlined progress across its prioritized oncology pipeline and reviewed full-year 2025 financial results, emphasizing a streamlined strategy centered on three clinical...
MarketBeat·8d ago
News Placeholder
Innate Pharma (NASDAQ:IPHA) Releases Earnings Results, Beats Expectations By $0.17 EPS
Innate Pharma (NASDAQ:IPHA - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.17. The business had revenue of $2.42 million during the quarter, compared to...
MarketBeat·8d ago
News Placeholder
Innate Pharma Reports Full Year 2025 Financial Results and Business Update
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today reported its business update and consolidated financial results for the year ending December 31...
Business Wire·9d ago
News Placeholder
Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announces that the Company will hold a conference call on Thursday, March 26, 2026 at 2 p.m. CET...
Business Wire·16d ago
News Placeholder
Innate Pharma (IPHA) Projected to Post Earnings on Thursday
Innate Pharma (NASDAQ:IPHA) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 26. (View Earnings Report at...
MarketBeat·16d ago
News Placeholder
Innate Pharma (IPHYF) Expected to Announce Quarterly Earnings on Thursday
Innate Pharma (OTCMKTS:IPHYF) will be releasing earnings before the market opens on Thursday, March 26. (View Earnings Report at...
MarketBeat·16d ago
News Placeholder
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Get Free Report) was the recipient of a significant decline in short interest in February. As of February 27th, there was short interest totaling...
MarketBeat·19d ago
<
1
2
...
>

Latest IPHA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.